ArticleMedical science monitor : international medical journal of experimental and clinical research2026
Recurrence Rate and Survival in 260 Patients With Oncocytic Thyroid Cancer According to Response to Initial Treatment - A Single-Institution Experience.
Article in Medical science monitor : international medical journal of experimental and clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Oncocytic thyroid carcinoma (OTC) is a rare disease. There is little information about risk factors for recurrence. The aim of our retrospective, single-institution study was to investigate the recurrence rate in OTC patients with and without an excellent response after initial treatment according to the 2025 American Thyroid Association guidelines response criteria based on type of initial intervention. MATERIAL AND METHODS Altogether, 260 patients with OTC (57 men, 203 women; mean age 60.35 years; range 16-90 years) treated from 1972 to 2024 were included. Initially, regional and distal metastases were diagnosed in 15 (6%) and 25 (10%) patients, respectively. Cox's multivariate regression model was used to identify the risk factors for recurrence. RESULTS The follow-up period ranged from 0.1 to 45.2 (median 7.9) years. Recurrence was diagnosed in 39 (17%) of the 235 patients without disease after initial treatment. Locoregional, distant, and combined locoregional and distant recurrence was diagnosed in 18, 14, and 7 patients, respectively. Among 154 patients with an excellent response, recurrence occurred in 6.5%, and among the 81 patients without an excellent response, it occurred in 36% (P<0.001). Independent risk factors for recurrence were: sex (males, hazard ratio (HR)=2.5, 95% CI 1.3-4.8; P=0.009), age (≥55 years, HR=2.7, 95% CI 1.2-5.8; P=0.012), pT stage (pT3 or pT4, HR=1.4, 95% CI 1.0-1.9; P=0.023), and residual tumor after surgery (R1 or R2 residual tumor, HR=1.2, 95% CI 1.07-1.3; P=0.001). The 5-year disease-free survival rate for the entire cohort was 88%, while the 10-year and 20-year disease-free survival rates were 79%, and 74%, respectively. CONCLUSIONS Recurrence rate in patients with and without an excellent response was 6.5% and 35%, respectively. Recurrence was more common in men, older patients, those with regional metastases, and those with residual tumor after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.